AUSTIN, Texas — Patients on dialysis who are hyporesponsive to anemia treatment will likely experience more red blood cell transfusions, according to data presented at the National Kidney Foundation Spring Clinical Meetings.“Hyporesponse (hypoR) to erythropoiesis-stimulating agents (ESAs) is associated with adverse events and poor outcomes leading to high health care
Sandy Thompson stopped working and qualified for Medicare based on disability at age 47 because of, as she puts it, “so many complicated [health] issues.” Now 61 years old, she’s
Sandy Thompson stopped working and qualified for Medicare based on disability at age 47 because of, as she puts it, “so many complicated [health] issues.” Now 61 years old, she’s
AUSTIN, Texas —Patients on dialysis who are hyporesponsive to anemia treatment have a higher risk for hospitalizations and death, according to data presented here. “Hyporesponse (hypoR) to erythropoiesis-stimulating agents (ESAs) is associated with adverse events,” Christine Ferro, BA, and colleagues wrote in a poster presented at the National Kidney Foundation Spring Clinical